BSPM [Biostar Pharmaceuticals,] 8-K: ex99-1.htm 2 EX-99.1
[ex99-1.htm 2 EX-99.1] [ex99-2.htm 3 EX-99.2]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operating Income of $16 – $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, an increase of 1200 basis-points compared to 59% in 2008. Management anticipates unaudited operating income, excluding non-cash charges, of]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue
[Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operating Income of $16 – $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, an increase of 1200 basis-points compared to 59% in 2008. Management anticipates unaudited operating income, excluding non-cash charges, of]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Provides Preliminary 2009 Results: Revenue of
[Biostar Pharmaceuticals, Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operatingome of $16 $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, anrease of 1200 basis-pointsmpared to 59% in 2008. Management anticipates unaudited operatingome, excluding non-cash charges, of approximately]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operatingome of $16 $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, anrease of 1200 basis-pointsmpared to 59% in 2008. Management anticipates unaudited operatingome, excluding non-cash charges, of approximately]
BSPM [Biostar Pharmaceuticals,] 8-K: Morgenstern, Svoboda & Baer CPA’s P.C. January 28,
[Morgenstern, Svoboda & Baer CPA’s P.C. January 28, 2010 100 F. Street, N.E. Re: Biostar Pharmaceuticals, Inc. Commission File No. 333-147363 Dear Sir or Madame: Yours very truly, Morgenstern, Svoboda & Baer CPA’s P.C. New York, New York EX-16.1 2 ex16-1.htm] [Biostar Pharmaceuticals, Inc. Announces Change of Auditor XIANYANG, China, January 28, 2010 (Xinhua-PRNewswire-FirstCall) About Mazars Hong Kong Mazars Hong Kong is part of the Mazars Group, an international, integrated and independent partnership, and as such is a member of the Praxity alliance, which ranks among the top 10 of international accounting firms in size and global billings. Mazars Hong Kong]
